ACCUMED INTERNATIONAL INC
SC 13D, 1996-12-17
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: NETPLEX GROUP INC, S-3/A, 1996-12-17
Next: ACCUMED INTERNATIONAL INC, S-3/A, 1996-12-17






<PAGE>

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934

Amendment No.:  *

Name of Issuer: Accumed International, Inc.

Title of Class of Securities:  Common Stock, $.01 par value

CUSIP Number:  004383105

          (Name, Address and Telephone Number of Person
       Authorized To Receive Notices and Communications)  

 Mr. Peter J. Cobos c/o Kingdon Capital Management Corporation,
 152 West 57th Street, New York, New York 10019, (212) 333-0100

     (Date of Event which Requires Filing of this Statement)

                         October 3, 1996

If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of
Rule 13d-1(b)(3) or (4), check the following box [   ].

Check the following box if a fee is being paid with this
statement [ ].  (A fee is not required only if the filing person:
(1) has a previous statement on file reporting beneficial
ownership of more than five percent of the class of securities
described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of
class.  See Rule 13d-7).

*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).



<PAGE>

CUSIP No. 004383105

1.  Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person

         Kingdon Capital Management Corporation  #13-3158796

2.  Check the Appropriate Box if a Member of a Group

         a.   
         b.   x

3.  SEC Use Only

4.  Source of Funds

         WC

5.  Check if Disclosure of Legal Proceedings is Required Pursuant
    to Items 2(d) or 2(e)

6.  Citizenship or Place of Organization

         Delaware

Number of Shares Beneficially Owned by Each Reporting Person
With:

7.  Sole Voting Power:

         1,143,000 shares

8.  Shared Voting Power:


9.  Sole Dispositive Power:

         1,143,000 shares

10. Shared Dispositive Power:


11. Aggregate Amount Beneficially Owned by Each Reporting Person

         1,143,000 shares

12. Check Box if the Aggregate Amount in Row (11) Excludes
    Certain Shares





                               -2-



<PAGE>

13. Percent of Class Represented by Amount in Row (11)

         5.21%

14. Type of Reporting Person

         CO

Item 1.  Security and Issuer

         This statement relates to shares of common stock, $.01
         par value (the "Common Stock") of Accumed International,
         Inc. ("ACMI").  ACMI's principal executive office is
         located at 920 North Franklin Street, Suite 402,
         Chicago, Illinois 60610

Item 2.  Identity and Background

         This statement is being filed on behalf of Kingdon
         Capital Management Corporation ("KCMC"), a Delaware
         corporation.  KCMC's principal business is to act as an
         investment adviser; its principal office is at 152 West
         57th Street, New York, New York 10019.

         Mr. Mark Kingdon is the sole shareholder, director and
         executive officer of KCMC.  Mr. Kingdon has not, during
         the last five years, been convicted in a criminal
         proceeding (excluding traffic violations or similar
         misdemeanors).  Mr. Kingdon has not, during the last
         five years, been a party to a civil proceeding of a
         judicial or administrative body of competent
         jurisdiction which resulted in a judgment, decree or
         final order enjoining future violations of, or
         prohibiting or mandating activities subject to, federal
         or state securities laws or finding any violations with
         respect to such laws.

         Mr. Kingdon is a citizen of the United States of
         America.

Item 3.  Source and Amount of Funds or Other Consideration.

         As of the date hereof, KCMC is deemed to beneficially
         own 1,143,000 shares of Common Stock.  All 1,143,000
         shares of Common Stock are held by entities and managed
         accounts over which KCMC has investment discretion.  The
         1,143,000 shares of Common Stock were purchased in open
         market transactions at an aggregate cost of
         $3,998,019.86.  The funds for the purchase of the Common
         Stock held in the entities and managed accounts over
         which KCMC has investment discretion have come from each


                               -3-



<PAGE>

         entity's or account's own funds.  No leverage was used
         to purchase any shares.

Item 4.  Purpose of Transactions.

         The shares of Common Stock deemed to be beneficially
         owned by KCMC were acquired for, and are being held for,
         investment purposes.

         KCMC has no plan or proposal which relates to, or would
         result in, any of the actions enumerated in Item 4 of
         the instructions to Schedule 13D.

Item 5.  Interest in Securities of Issuer.

         As of the date hereof, KCMC is deemed to be the
         beneficial owner of 1,143,000 shares of Common Stock.
         Based on ACMI's filing on Schedule 10Q on November 13,
         1996, as of November 11, 1996, there were 21,934,710
         shares of Common Stock outstanding.  Therefore, KCMC is
         deemed to beneficially own 5.21% of the outstanding
         shares of Common Stock.  KCMC has the sole power to
         vote, direct the vote, dispose of or direct the
         disposition of all the shares of Common Stock that it is
         currently deemed to beneficially own.

Item 6.  Contracts, Arrangements, Understandings or
         Relationships with Respect to Securities of the Issuer

         KCMC has no contract, arrangement, understanding or
         relationship with any person with respect to the Common
         Stock.

Item 7.  Material to be Filed as Exhibits.

         Attached hereto as Exhibit A is a description of the
         transactions in the Common Stock that have been effected
         by KCMC since 60 days prior to October 3, 1996.















                               -4-



<PAGE>


         Signature

         The undersigned, after reasonable inquiry and to the
best of its knowledge and belief, certifies that the information
set forth in this statement is true, complete and correct.

December 17, 1996



Kingdon Capital Management Corporation


By: /s/ Peter J. Cobos        

    __________________________
    Peter J. Cobos, Controller



































                               -5-



<PAGE>

                            EXHIBIT A

                    SCHEDULE OF TRANSACTIONS

                   Shares of 
                   Common Stock        Price Per Share
Date               Purchased           (Not Including Commission)
____               _______________     _________________________ 

10/3/96                190,000              $4.5











































48400002.AF5



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission